Navigation Links
Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
Date:4/30/2008

Dr. Bill Poland Will Present on the Strategic Use of Incorporating Adherence Data into Clinical Trial Predictions of Antiviral Therapies

MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, has been invited to present at a Drug Information Association (DIA) workshop on using patient adherence data at the University of California Washington Center in Washington, DC. Dr. Poland will present on May 6, 2008, joining other leading experts from the pharmaceutical industry and academia in a session on the utility of incorporating adherence estimates in the design of clinical trials intended to learn about exposure-response relationships.

The workshop will provide a forum for scientific discussion and collaborative exchange on opportunities for the use of new methods in the conduct and interpretation of clinical trials through the use of reliable patient adherence data. Dr. Poland's presentation, entitled "Incorporating Adherence into Antiviral Clinical Trial Predictions", will describe how quantitative models of patient compliance for new antiviral agents can be linked with predictive drug-disease models to optimize dosing strategies and support clinical trial simulations. Further information can be found at http://www.diahome.org.

"Antiviral drugs present special therapeutic challenges to development teams, including patient compliance with long-term treatment regimens," said Shawn O'Connor, president, CEO and chairman of Pharsight. "To support planning and quantitative decision-making for antiviral development, it is important to account for highly variable patient compliance in the complexities of viral dynamics modeling. Model-based approaches can lead to enhanced clinical trial designs and in developing strategies to optimize tradeoffs such as that between patient compliance and dosing regimen, as well as inform better clinical program investment decisions. Pharsight is pleased to present at this important adherence workshop and to continue its contributions at DIA events, where we look forward to sharing our experience with industry colleagues and interacting with fellow practitioners of modeling and simulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Strengthens Senior Management Team
2. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
3. Pharsight Signs New Diabetes Meta-Database Customer
4. Pharsight to Present at eClinical Forum
5. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
6. FDA and Pharsight Continue to Collaborate Under CRADA
7. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
8. Pharsight Achieves $7.3 Million in Quarterly Revenue
9. Pharsight Expands Global Consulting Services Teams
10. Pharsight to Host European Software Conference
11. Pharsight Files Application for Nasdaq Capital Market Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
Breaking Medicine Technology: